Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.

Ionis Pharmaceuticals and Janssen strengthened their alliance with a second deal for gastrointestinal drugs. Janssen put up $5 million to secure the licensing of Ionis’ antisense drug, IONIS-JBI2-2.5RX.